spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  capecitabine 

 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 5 Jul 2024
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Dec 2020
FDA Approves Novadoz Pharmaceuticals Toremifene and Aminocaproic Acid, Bolstering their Continued Growth in Generics
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Aug 2014
Mylan Launches Generic Xeloda(R) Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2013
Lorus Therapeutics Appoints New Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Oct 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2011
Fox Chase Cancer Center Study Evaluating the Safety of Concurrent Chemotherapy and Selective Internal Radiation Therapy using SIR-Spheres(R) Microspheres Released at 2011 American Society of Clinical Oncology Annual Meeting
Devices Oncology
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2010
Genentech Provides Update on FDA Application for T-DM1
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jul 2010
Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2010
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Nov 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2009
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Biopharmaceuticals Oncology Generics Litigation
 HSMN NewsFeed - 2 Apr 2009
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2009
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2008
VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid(TM)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2008
Adherex Receives Orphan Drug Designation for ADH-1 in Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2008
Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2008
Xeloda(R) Combination Therapy in Esophagogastric Cancer Highlighted in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2007
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2007
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2007
Myriad Genetics Launches New Molecular Diagnostic Test
Diagnostics Oncology
 HSMN NewsFeed - 6 Jul 2007
Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Glaxosmithkline Reports Positive New Data on Tykerb(R)(Lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Xeloda(R) Plus Avastin(R) Combination Delays Disease Progression in Women with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Biweekly Xeloda(R) Dosing Regimen is Well Tolerated in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 22 May 2007
NCCN Updates Esophageal and Gastric Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Mar 2007
Roche Submits Application to the FDA for use of XELOX (Xeloda(R) plus oxaliplatin) With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2007
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R) (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Feb 2007
GSK Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2007
Results Show XELOX (Xeloda(R) plus oxaliplatin) Provides Equivalent Overall Patient Survival Compared to FOLFOX in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Dec 2006
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit in Patients with Advanced Breast Cancer
Biopharmaceuticaals Oncology
 HSMN NewsFeed - 13 Dec 2006
Lapatinib (Tykerb(R)) to be Evaluated in Early Stage Disease in Adjuvant Breast Cancer Settings Internationally
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Xeloda(R) Combination Meets Primary Endpoint in International Phase III Advanced Colorectal Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Oct 2006
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
XELOX (Xeloda(R) + oxaliplatin) Shown to be as Effective as Current Standard in the Treatment of Advanced Colorectal Cancer for Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2006
Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) in Patients With Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2006
Sirtex Announces Clinical Trial Evaluating the Use of SIR-Spheres(R) Microspheres with Xeloda(R) for Metastatic Liver Cancer
Devices Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 44

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 44 additional stories matching:
capecitabine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.